A pharmaceutical composition comprising candesartan cilexetil and amlodipine besylate having a composition selected from the embodiments a to f as specified in the table below, Embodiment a [mg] b [mg] c [mg] d [mg] e [mg] f [mg] Candesartan Cilexetil 16.0 16.0 16.0 16.0 16.0 16.0 Lactose Monohydrate 177.8 / 177.8 177.8 177.8 81.0 Cellulose, Microcrystalline / 177.8 / / / / Maize Starch 40.0 40.0 40.0 40.0 40.0 20.0 Ferric oxide yellow 0.06 0.06 0.06 0.06 0.06 0.06 Ferric oxide red 0.12 0.12 0.12 0.12 0.12 0.12 Macrogol 8000 5.2 5.2 5.2 5.2 5.2 2.6 Hydroxypropyl cellulose (Klucel TM EF) 16.0 16.0 16.0 8.0 Hydroxypropyl cellulose (Klucel TM LF) 16.0 16.0 Water, Purified* q.s. q.s. q.s. q.s. q.s. q.s. Calcium carboxymethyl cellulose 4.0 4.0 / 4.0 4.0 2.0 Sodium carboxymethyl cellulose / / 4.0 / / / Magnesium stearate 0.8 0.8 0.8 0.8 0.8 0.4 Amlodipine besylate 13.9 13.9 13.9 13.9 13.9 13.9 Cellulose, Microcrystalline 180.9 180.9 180.9 180.9 180.9 59.1 Starch, Pregelatinised / 60.0 60.0 60.0 60.0 18.0 Maize Starch 60.0 / / / / / Sodium Starch Glycolate 21.00 21.00 21.00 21.00 / 7.5 Potassium polacrilin / / / / 21.00 / Silica, Colloidal Anhydrous 1.25 1.25 1.25 1.25 1.25 0.50 Magnesium Stearate 3.0 3.0 3.0 3.0 3.0 1.0 *Not present in the final dosage form. Evaporates during the process. which is obtainable by the following manufacturing method: (i) homogeneously mixing amlodipine besylate, microcrystalline cellulose, binder (maize starch (embodiment a) or pregelatinised starch (embodiments b-f), sodium starch glycolate (embodiments a-d and f) or sodium carboxymethyl cellulose (embodiment e)), silica, colloidal anhydrous and magnesium stearate to obtain the powder blend; (ii) separately dissolving hydroxypropyl cellulose in water, then adding Macrogol 8000 and dispersing candesartan cilexetil in said solution to obtain a water dispersion; (iii) granulating lactose monohydrate (embodiments a and c-f) or microcrystalline cellulose (embodiment b), ferric oxide, and maize starch with said water dispersion in a fluid bed granulator; (iv) adding calcium carboxymethyl cellulose (embodiments a-b and d-f) or sodium carboxymethyl cellulose (embodiment c) and magnesium stearate to the granules of step (iii) to obtain a granulated blend; and (v) compressing both blends of steps (i) and (iv) into bilayer tablets. (i) homogeneously mixing amlodipine besylate, microcrystalline cellulose, binder (maize starch (embodiment a) or pregelatinised starch (embodiments b-f), sodium starch glycolate (embodiments a-d and f) or sodium carboxymethyl cellulose (embodiment e)), silica, colloidal anhydrous and magnesium stearate to obtain the powder blend; (ii) separately dissolving hydroxypropyl cellulose in water, then adding Macrogol 8000 and dispersing candesartan cilexetil in said solution to obtain a water dispersion; (iii) granulating lactose monohydrate (embodiments a and c-f) or microcrystalline cellulose (embodiment b), ferric oxide, and maize starch with said water dispersion in a fluid bed granulator; (iv) adding calcium carboxymethyl cellulose (embodiments a-b and d-f) or sodium carboxymethyl cellulose (embodiment c) and magnesium stearate to the granules of step (iii) to obtain a granulated blend; and (v) compressing both blends of steps (i) and (iv) into bilayer tablets. <EOS>